Clearmind submits FDA recommendations on psychedelic therapies
VANCOUVER, Canada - Clearmind Medicine Inc. (NASDAQ:CMND) has recently submitted recommendations to the U.S. Food and Drug Administration concerning the potential therapeutic applications of psychedelic drugs, as reported by the company in a press release. In response to the FDA's public hearing on the matter, Clearmind filed its comments under the docket number FDA-2026-N-7542. The recommendations center around non-hallucinogenic neuroplastogens and improving patient access to such treatments.
Clearmind's proposals encompass guidance for self-administration and at-home therapies, as well as the simplification of regulatory processes, increased access to clinical trials, and the utilization of Breakthrough Designation. The company highlighted its ongoing clinical trials at prestigious institutions such as Yale University and Johns Hopkins University, which have yielded data on neuroplastogenic compounds that possess therapeutic benefits while omitting hallucinogenic effects.
Furthermore, Clearmind has called for collaborative research and clinical partnerships with key federal entities, including the U.S. Department of Veterans Affairs, the U.S. Department of Health and Human Services, and what the company referred to as the U.S. Department of War. The aim is to pilot neuroplastogenic candidates specifically for Alcohol Use Disorder and other conditions.
CEO Dr. Adi Zuloff-Shani emphasized the company's dedication to contributing to the ongoing dialogue surrounding patient access, responsible development, and the future utilization of psychedelic-derived therapies. This submission follows a previous briefing by Clearmind’s Chief of Global Impact on September 14, 2026, where the company presented patient access and clinical trial insights to an FDA-convened federal panel.
Clearmind is currently focusing on the development of non-hallucinogenic psychedelic-derived compounds for neuropsychiatric, metabolic, and addiction disorders. The company currently owns nineteen patent families, including 32 granted patents.
Rewritten by urgent.news; may contain errors — check the original.